In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 41933-33-9, name is 2-Benzyl-4,5-dichloropyridazin-3(2H)-one, introducing its new discovery. Quality Control of 2-Benzyl-4,5-dichloropyridazin-3(2H)-one
AZABICYCLIC HETEROCYCLES AS CANNABINOIND RECEPTOR MODULATORS
The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I and Formula II: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3 and R4 are described herein.
We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 41933-33-9, and how the biochemistry of the body works.Quality Control of 2-Benzyl-4,5-dichloropyridazin-3(2H)-one
Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N3199 – PubChem